Shares in NeuroSearch A/S surged more than 50 percent Friday on news of its largest ever deal, a US$80 million pact with Boehringer Ingelheim GmbH to develop its candidate Alzheimer’s and Parkinson’s drug, NS2330. (BioWorld International)